Heat Biologics (HTBX) Receives Analyst Rating

Heat Biologics (HTBX) : 2 brokerage houses believe that Heat Biologics (HTBX) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 2 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Heat Biologics (HTBX) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $8 and the lowest price target forecast is $3. The average forecast of all the analysts is $5.38 and the expected standard deviation is $3.71.


Also, Roth Capital initiates coverage on Heat Biologics (NASDAQ:HTBX) . The global brokerage major announces a current price target of $2.75 per share. Analysts at the Roth Capital have a current rating of Buy on the shares. The rating by the firm was issued on June 20, 2016.

Heat Biologics (NASDAQ:HTBX): The stock opened in the green at $1.44 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.44 and a low of $1.35 for the day. The stock did not find buyers even at the lows and closed at $1.39 recording a loss of -0.71%. 503,393 shares exchanged hands during the trading day. The stock had closed at $1.4 in the previous days trading.

Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.